Van ECK Associates Corp Sells 1,334,536 Shares of CVS Health Corporation $CVS

Van ECK Associates Corp cut its holdings in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 85.5% during the second quarter, Holdings Channel.com reports. The fund owned 226,203 shares of the pharmacy operator’s stock after selling 1,334,536 shares during the period. Van ECK Associates Corp’s holdings in CVS Health were worth $23,401,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Caitong International Asset Management Co. Ltd lifted its holdings in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares in the last quarter. Swiss RE Ltd. bought a new position in CVS Health in the 4th quarter worth approximately $26,000. Kilter Group LLC purchased a new stake in CVS Health during the 2nd quarter valued at approximately $27,000. Sankala Group LLC bought a new stake in shares of CVS Health during the fourth quarter valued at approximately $28,000. Finally, Global Trust Asset Management LLC lifted its holdings in shares of CVS Health by 344.8% in the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after buying an additional 300 shares in the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on CVS. Bank of America upped their target price on shares of CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Wells Fargo & Company lifted their price target on shares of CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Cantor Fitzgerald increased their price objective on shares of CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Barclays raised their price objective on CVS Health from $106.00 to $108.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Finally, Wall Street Zen raised CVS Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Twenty-two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.17.

View Our Latest Analysis on CVS Health

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Pharmacy momentum supports the turnaround case. Rising prescription volumes, gains associated with Rite Aid and improving pharmacy profitability could provide support for CVS’s second-half outlook. This adds to the company’s recent earnings momentum, including revenue growth and an earnings beat in its latest reported quarter. How CVS’ Pharmacy and Consumer Wellness Is Positioned for H2 2026
• Positive Sentiment: Updated flu vaccines are now available nationwide. CVS Pharmacy and MinuteClinic are offering the 2026–2027 vaccines, while expanded testing and treatment services may increase seasonal customer traffic. A company survey found that more than 60% of consumers are likely to get a flu shot, though the earnings effect is likely to be seasonal and modest. CVS Pharmacy and MinuteClinic Now Offering Updated Flu Vaccines Nationwide
• Positive Sentiment: Value-focused coverage is reinforcing rebound expectations. Zacks characterizes CVS as a potential long-term value stock, while Trefis notes that the company’s historical drawdowns have often eventually recovered. These are sentiment and valuation arguments rather than new financial guidance, but they may attract investors seeking a healthcare turnaround at a relatively reasonable valuation. Why CVS Health Is a Top Value Stock for the Long-Term
• Neutral Sentiment: ACA insurer exits create both opportunity and uncertainty. Cigna, Molina and other carriers are leaving Obamacare exchanges in 2027. The disruption could create enrollment opportunities for Aetna, CVS’s insurance business, but also highlights regulatory, pricing and membership risks across the sector. All the Insurers Exiting ACA Obamacare Exchanges for 2027
• Negative Sentiment: Political pressure on vertically integrated healthcare companies remains a risk. Mark Cuban’s support for breaking up “big medicine” adds to scrutiny of insurers, pharmacy benefit managers and large healthcare platforms. No specific policy action against CVS was announced, but potential structural or regulatory changes could weigh on sentiment. Mark Cuban Backs Plan to Break Up Big Medicine

CVS Health Trading Up 0.1%

Shares of CVS opened at $93.15 on Monday. The stock has a market capitalization of $119.14 billion, a PE ratio of 24.64, a P/E/G ratio of 0.91 and a beta of 0.61. The company’s fifty day moving average is $101.42 and its 200 day moving average is $89.55. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a fifty-two week low of $69.51 and a fifty-two week high of $110.68.

CVS Health (NYSE:CVS – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. During the same quarter last year, the business earned $1.81 earnings per share. CVS Health’s quarterly revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Sell-side analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were given a $0.665 dividend. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.9%. CVS Health’s dividend payout ratio (DPR) is currently 70.37%.

About CVS Health

(Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Featured Stories

• Five stocks we like better than CVS Health
• Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
• Rubrik’s AI Security Bet Could Power the Next Leg Higher
• Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
• Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).